Mariko Kobayashi

发表

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Gastroenterology.

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prolonged hepatitis after acute infection with genotype H hepatitis B virus.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.

K. Tadokoro, Toshikazu Yamaguchi, Toru Egashira, 2006, Journal of virological methods.

Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus

K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, 2012, Journal of Gastroenterology.

Correlation between hepatitis B virus surface antigen level and alpha‐fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, H. Kumada, 2013, Journal of medical virology.

Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Infection Treatment of Hepatitis C Virus Genotype 1 Variants for Prediction of Efficacy of Utility of Detection of Telaprevir-Resistant

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013 .

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients

Yoshiyuki Suzuki, H. Tsuda, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Emergence of telaprevir‐resistant variants detected by ultra‐deep sequencing after triple therapy in patients infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of medical virology.

Long‐term interferon monotherapy reduces the risk of HCV‐associated hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Yusuke Nakamura, K. Chayama, Y. Karino, 2011, The Journal of infectious diseases.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2010, Hepatology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐up

N. Hiraga, Yoshiyuki Suzuki, M. Kobayashi, 2005, Journal of medical virology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

K. Chayama, H. Handa, Yoshiyuki Suzuki, 1999, Journal of medical virology.

Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Genotypic subtyping of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Journal of gastroenterology and hepatology.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Gut and liver.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Hepatology International.

Correlation of Histopathological Features andGenetic Variations with Prognosis of JapanesePatients with Nonalcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Scandinavian journal of gastroenterology.

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Digestive Diseases and Sciences.

Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Clinical Microbiology.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Oncology.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of Clinical Microbiology.

Functional Analysis of Hepatitis C Virus Envelope Proteins, Using a Cell-Cell Fusion Assay

Mariko Kobayashi, I. Singh, Ila R Singh, 2006, Journal of Virology.

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Scandinavian journal of gastroenterology.

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Oncology.

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology communications.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, BMC Gastroenterology.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, BMC Gastroenterology.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology communications.

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology communications.

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, BMC Gastroenterology.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2019, Internal medicine.

Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis

H. Yamanaka, Kazuhiko Yamamoto, N. Miyasaka, 2015, Modern rheumatology.

Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of medical virology.

Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Performance of autotaxin as a serum marker for liver fibrosis

K. Koike, M. Kurano, J. Aoki, 2018, Annals of clinical biochemistry.

The Superiority of Laparoscopic Examination in Predicting Hepatocellular Carcinoma after Inteferon Therapy for Chronic Type C Hepatitis

K. Chayama, A. Tsubota, K. Ikeda, 1997 .

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study

T. Matsui, H. Ogata, T. Hibi, 2020, Intestinal research.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C

K. Chayama, K. Ikeda, H. Kumada, 1991, Hepatology.

Interferon therapy for HCV-RNA positive chronic hepatitis.

K. Chayama, A. Tsubota, K. Ikeda, 1993 .

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Journal of Gastroenterology.

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

K. Chayama, Y. Karino, N. Hiramatsu, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Genetic polymorphism in cyclooxygenase‐2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C

Takayoshi Ito, H. Kumada, Mariko Kobayashi, 2012, Journal of viral hepatitis.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of hepatology.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Journal of medical virology.

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Effect of lymphoblastoid alfa-interferon in patients with chronic hepatitis C having different genotypic subtype of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Gastroenterologia Japonica.

A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.

H. Kumada, N. Akuta, Mariko Kobayashi, 2007, Journal of virological methods.

Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Digestive Diseases and Sciences.

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study

H. Ogata, T. Hibi, Mariko Kobayashi, 2020, Intestinal research.

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study

T. Hibi, Yasuo Suzuki, Mariko Kobayashi, 2020, Intestinal research.

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype

K. Chayama, A. Tsubota, Y. Suzuki, 1998, Journal of Gastroenterology.

Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B

Yoshiyuki Suzuki, Mio Tanaka, M. Kobayashi, 2014, Journal of Gastroenterology.

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of Clinical Virology.

Prevalence of HCV genotype among patients with chronic liver diseases in the Tokyo metropolitan area

K. Chayama, K. Ikeda, H. Kumada, 1994, Journal of Gastroenterology.

Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Clinical features of hepatitis B virus genotype A in Japanese patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of hepatology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of Gastroenterology.

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Drug design, development and therapy.

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology communications.

Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Alimentary pharmacology & therapeutics.

Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009 .

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

M. Imamura, K. Chayama, T. Okanoue, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Measurement of hepatitis B virus core‐related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

M. Imamura, K. Chayama, T. Okanoue, 2006, Liver international : official journal of the International Association for the Study of the Liver.